Related Experiment Videos
Exocrine pancreatic function in man after cytotoxic treatment
Acta Hepato-Gastroenterologica
|December 1, 1975
Summary
Cyclophosphamide therapy did not significantly alter exocrine pancreatic function. However, combined cytotoxic treatments and Myleran maintenance therapy were associated with reduced pancreatic enzyme activities, impacting digestive health.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Cancer therapies can affect various organ systems.
- The exocrine pancreas plays a crucial role in digestion.
- Understanding treatment side effects is vital for patient care.
Purpose of the Study:
- To evaluate the impact of cyclophosphamide and combined cytotoxic therapies on exocrine pancreatic function.
- To compare pancreatic function in cancer patients undergoing different treatment regimens versus controls.
Main Methods:
- Secretin-pancreozymin test used to assess exocrine pancreatic function.
- Patients with malignant disease studied before and after specific therapies.
- Comparison groups included those on maintenance therapy and healthy controls.
Main Results:
- Massive-dose or continued cyclophosphamide therapy showed no significant changes in duodenal secretion volume or outputs.
- Combined cytotoxic treatment led to decreased amylase, lipase, and sometimes trypsin activities.
- Myleran maintenance therapy resulted in reduced trypsin and amylase, with slight decreases in chymotrypsin and lipase.
Conclusions:
- Cyclophosphamide therapy appears to have minimal impact on exocrine pancreatic function.
- Combined cytotoxic regimens and Myleran maintenance therapy can negatively affect pancreatic enzyme output.
- Further research may be needed to mitigate these pancreatic side effects.